C4 Therapeutics expands Roche collaboration for degrader-antibody conjugates

C4 Therapeutics says it has expanded its long-term partnership with Roche through a new collaboration focused on degrader-antibody conjugates for oncology.

The company said the agreement covers two oncology targets, with an option to add a third. Under the deal, C4 Therapeutics will develop degrader payloads, while Roche will conjugate them to targeted antibodies.

C4 Therapeutics said the collaboration includes a $20 million upfront payment and could generate more than $1 billion in discovery, development and commercial milestones, plus royalties.

The announcement builds on an earlier Roche relationship between the two companies and adds another large-bet licensing deal to the biotech sector’s list of platform partnerships. C4 Therapeutics said the new agreement is intended to advance a new class of targeted cancer therapies.

The company disclosed the collaboration on April 9, 2026. No timeline for first milestone events or development readouts was included in the initial announcement.